A1862
Alpidem
≥98% (HPLC), powder
别名:
6-Chloro-2-(4-chlorophenyl)-N,N-dipropyl-imidazo[1,2-a]pyridine-3-acetamide, 6-Chloro-2-(p-chlorophenyl)-N,N-dipropylimidazo(1,2-a)pyridine-3-acetamide, Ananxyl, SL 80.0342-00
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H23Cl2N3O
化学文摘社编号:
分子量:
404.33
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
产品名称
Alpidem, ≥98% (HPLC), powder
InChI
1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3
SMILES string
CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c3ccc(Cl)cc3
InChI key
JRTIDHTUMYMPRU-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to tan
solubility
DMSO: ≥10 mg/mL
originator
Sanofi Aventis
storage temp.
2-8°C
Gene Information
human ... TSPO(706)
Biochem/physiol Actions
Alpidem is a potent antagonist of peripheral benzodiazepine receptor (PBR) that is located on the outer mitochondrial membrane and interacts with the mitochondrial permeability transition (MPT) pore. Alpidem is an anxiolytic drug from the imidazopyridine family. Alpidem acts selectively on the α3 receptor subtype and to a lesser extent at the α1 subtype (Kd of 0.33nM and 1.67nM respectively), of the benzodiazepine receptor.
Alpidem is a potent peripheral benzodiazepine receptor (PBR) antagonist.
Features and Benefits
This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
V Baty et al.
Gastroenterologie clinique et biologique, 18(12), 1129-1131 (1994-01-01)
Acute hepatitis related to psychotropic drugs has been rarely reported with anxiolytic treatments. Alpidem (Ananxyl) is a new imidazopyridine derivative with anxiolytic properties which was launched in October 1991. Several cases of acute hepatitis, some severe, were described with this
[A new case of hepatitis after alpidem monotherapy].
B Prat et al.
Gastroenterologie clinique et biologique, 18(10), 903-904 (1994-01-01)
[Subfulminant hepatitis caused by alpidem and treated by liver transplantation].
P Ausset et al.
Gastroenterologie clinique et biologique, 19(2), 222-223 (1995-02-01)
Y Gaillard et al.
Journal of chromatography, 622(2), 197-208 (1993-12-22)
A rapid twin-column gas chromatographic (GC) method for simultaneous screening and determination of commonly prescribed benzodiazepines and other new anxiolytics from plasma is described. Identical fused-silica Ultra 2 (5% phenyl methyl silicone) columns were connected to nitrogen-phosphorus and electron-capture detectors.
M Anzini et al.
Journal of medicinal chemistry, 39(21), 4275-4284 (1996-10-11)
Alpidem (1), the anxiolytic imidazopyridine, has nanomolar binding affinity for both the central benzodiazepine receptor (CBR) and the peripheral benzodiazepine receptor (PBR). A novel class of PBR ligands related to alpidem has been designed by comparing the interaction models of
商品
We offer many products related to GABAA receptors for your research needs.
DISCOVER Bioactive Small Molecules for Neuroscience
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持